The role of serum biomarkers in the diagnosis of nonalcoholic fatty liver disease

Фадеенко, Галина Дмитриевна; Kushnir, I. E.; Можина, Т. Л.; Chernova, V. M.; Solomentseva, T. A.

doi:10.30978/mg-2019-3-58

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metabolically active cells such as adipocytes secrete numerous anti-inflammatory cytokines and chemokines, adiponectin, and leptin in obesity [19]. According to many authors, TNF-α and interleukin-6 play the most important role in the pathogenesis of NAFLD among inflammatory mediators [11,12,13,20]. They are non-adipose tissue-specific cytokines but have a significant impact on the metabolism of fats and carbohydrates [21].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic abnormalities in patients with non-alcoholic fatty liver disease with immune response to SARS-CoV-2

Stepanov,

Didenko,

Klenina

et al. 2024

GASTRO

View full text Add to dashboard Cite

Background. It is known that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can directly infect hepatocytes. At the same time, overweight and obesity are surrogate markers of the adverse effects of coronavirus disease 2019 (COVID-19). The purpose of the study: to evaluate changes in lipid and carbohydrate metabolism and their indices in the serum of patients with non-alcoholic fatty liver disease (NAFLD) with an immune response to SARS-CoV-2. Materials and methods. We studied 37 patients with NAFLD who had IgG to SARS-CoV-2. All patients were divided into two groups: group I consisted of 19 participants who were PCR-negative for SARS-CoV-2, group II included 18 patients who had COVID-19, as confirmed by PCR testing. The content of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), glucose, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol (VLDL-C), atherogenicity coefficient, insulin resistance indices (HOMA-IR), TG to glucose (TG/Gly) and TG to HDL-C (TG/HDL-C) ratio were assessed in all patients. Results. Among patients with NAFLD with an immune response to SARS-CoV-2, dyslipidemia manifested by a probable increase in the median TG content in groups I and II by 2.5 and 3.4 times (р = 0.0001), respectively; TC — by 1.2 times (р = 0.0425) in both groups, with a tendency to increase; VLDL-C — by 1.8 (р = 0.010) and 2.5 times (р = 0.0022), respectively, and a decrease in the median content of HDL-C by 1.7 (р = 0.0016) and 1.9 times (р = 0.0008), respectively, in blood serum. The identified changes led to a statistically significant increase in the median atherogenicity coefficient in groups I and II — by 2.2 (р = 0.0036) and 2.5 times (р = 0.007). An increase in the HOMA-IR did not have a statistically significant difference between the groups: in group I, this index increased by 3.1 times (p < 0.05) compared with the controls, in group II — by 3 times (p < 0.05). In addition, patients in both groups had a statistically significant increase in TG/Gly and TG/HDL-C ratio compared to controls. However, the detected changes were more pronounced in group II, where TG/Gly and TG/HDL-C levels were 1.5 (р = 0.038) and 1.9 times (р = 0.035), respectively, higher than in group I. Conclusions. Patients with an immune response to SARS-CoV-2 with NAFLD have disorders of lipid and carbohydrate metabolism. At the same time, the signs of dyslipidemia were more pronounced in participants with a history of SARS-CoV-2. TG/Gly and TG/HDL-C ratio should be included in the diagnostic algorithm for assessing insulin resistance in patients with COVID-19 who are overweight or obese.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Cellular damage the main pathogenetic mechanisms of NAFLD/NASH [12,13]. Recent studies have begun to shed light on the relationship between liver steatosis, which until now was considered a purely "metabolic disease," and IR, which is associated with obesity and type 2 diabetes mellitus [7].…”

Section: Chondrocytementioning

confidence: 99%

Metabolic abnormalities in patients with non-alcoholic fatty liver disease with immune response to SARS-CoV-2

Stepanov,

Didenko,

Klenina

et al. 2024

GASTRO

View full text Add to dashboard Cite

show abstract

“…Комплексне лікування ГЕРХ полягає в модифікації способу життя, корекції дієти, медикаментозної терапії, а при неефективності медикаментозного лікування рекомендоване хірургічне втручання. Для стандартного медикаментозного лікування ГЕРХ застосовуються препарати, що блокують кислотну секрецію (блокатори протонної помпи, Н 2 -блокатори гістамінових рецепторів), антациди та прокінетики [1,3,16,17]. Терапія часто має довготривалий, іноді пожиттєвий характер, а в деяких випадках не приносить бажаного ефекту і вимагає хірургічної корекції [5,6,15].…”

unclassified

Gastroesophageal Reflux Disease – Is the Modern Treatment Standarts Sufficient to Solve the Problem?

Pliatsko¹

2017

NTSN MS

View full text Add to dashboard Cite

Медикаментозне лікування гастроезофагеальної рефлюксної хвороби (ГЕРХ), як однієї з найбільш поширених захворювань органів травлення складається з препаратів, що блокують кислотну секрецію (блокатори протонної помпи, Н 2-блокатори гістамінових рецепторів), антацидів та прокінетиків. Лікування є довготривалим, у випадках резистентності вимагає хірургічного втручання. Враховуючи, що основними патогенетичними механізмами ГЕРХ є ретроперистальтика та слабість нижнього діафрагмального сфінктера, то дану терапію можна вважати симптоматичною, так як основний її вплив спрямований на блокування кислотопродукції. При патогенетичному підході слід встановити причини дисфункції кадіо-езофагального відділу та порушення моторики. Найчастіше такі порушення виникають внаслідок патології хребта та хронічних захворювань дуоденально-біліарної зони. Запровадження патогенетичної терапії ГЕРХ в комплексі із стандартним підвищить ефективність лікування даної патології.

show abstract

The potential role of kallistatin as a new biomarker in non-invasive diagnostics of non-alcoholic fatty liver disease with hypertension

Babak¹,

Zhelezniakova²,

Rozhdestvenska³

2019

Shidnoevr. z. vnutr. simejnoi med.

View full text Add to dashboard Cite

The role of serum biomarkers in the diagnosis of nonalcoholic fatty liver disease

Cited by 4 publications

References 0 publications

Metabolic abnormalities in patients with non-alcoholic fatty liver disease with immune response to SARS-CoV-2

Metabolic abnormalities in patients with non-alcoholic fatty liver disease with immune response to SARS-CoV-2

Gastroesophageal Reflux Disease – Is the Modern Treatment Standarts Sufficient to Solve the Problem?

The potential role of kallistatin as a new biomarker in non-invasive diagnostics of non-alcoholic fatty liver disease with hypertension

Contact Info

Product

Resources

About